^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PDGFRB (Platelet Derived Growth Factor Receptor Beta)

    i
    Other names: PDGFRB, Platelet Derived Growth Factor Receptor Beta, Platelet-Derived Growth Factor Receptor, Beta Polypeptide, Beta-Type Platelet-Derived Growth Factor Receptor, Platelet-Derived Growth Factor Receptor Beta, Platelet-Derived Growth Factor Receptor 1, CD140 Antigen-Like Family Member B, PDGF-R-Beta, PDGFR-Beta, PDGFR-1, PDGFR1,Beta Platelet-Derived Growth Factor Receptor, Activated Tyrosine Kinase PDGFRB, CD140b Antigen, NDEL1-PDGFRB , CD140B, IBGC4, JTK12, PENTT, IMF1 , KOGS
    4d
    Paeoniflorin Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by SYK/SH3BP2 Signaling Pathway. (PubMed, Research (Wash D C))
    PF effectively attenuated hepatic metabolic dysregulation, inflammation, and fibrotic activation through inhibition of this pathway. Our work provided the first evidence establishing the SYK/SH3BP2 signaling axis as a pivotal pathway in MASLD progression, unveiling novel therapeutic targets while furnishing a mechanistic foundation for PF's potential application in MASLD treatment.
    Journal
    |
    PDGFRB (Platelet Derived Growth Factor Receptor Beta) • IL6 (Interleukin 6) • CD36 (thrombospondin receptor) • SYK (Spleen tyrosine kinase) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • CCL2 (Chemokine (C-C motif) ligand 2) • COL1A1 (Collagen Type I Alpha 1 Chain) • FASN (Fatty acid synthase) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • IL1B (Interleukin 1, beta) • NECTIN1 (Nectin Cell Adhesion Molecule 1) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    4d
    TGFBI promotes liver fibrosis through remodeling the profibrotic microenvironment by a positive feedback regulatory loop. (PubMed, Commun Biol)
    Elevated PDGF-B reversely stimulates TGFBI production in macrophages, which creates a positive feedback loop. This TGFBI-mediated interaction between HSCs and macrophages remodels the profibrotic microenvironment to promote liver fibrosis, identifying a potential therapeutic target.
    Journal
    |
    PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD9 (CD9 Molecule) • TGFBI (Transforming Growth Factor Beta Induced)
    11d
    From multi-omics to functional validation: the PTMRS stratifies TME and positions PDGFRB in CRC biology. (PubMed, Front Immunol)
    PDGFRB was validated as a core node within the PTMRS network: activation of PDGFRβ in human colonic fibroblasts promoted CRC cell proliferation and migration, whereas sunitinib attenuated and reversed these effects...These findings suggest that PTMRS may help identify patients who could benefit from combining immunotherapy with therapies targeting PDGFRβ or other PTM-related pathways. Further validation in in vivo models and prospective clinical cohorts is needed.
    Journal • IO biomarker
    |
    PDGFRB (Platelet Derived Growth Factor Receptor Beta)
    |
    sunitinib
    11d
    Targeted Therapy for a Rare PDGFRB-Rearranged Myeloproliferative Neoplasm: A Case Report. (PubMed, Int J Mol Sci)
    This allowed for targeted therapy with a tyrosine kinase inhibitor (TKI), leading to molecular remission monitored by RT-qPCR. This case highlights how a multidisciplinary approach can identify atypical transcripts in MPN, guiding targeted therapy with TK inhibitors, thus resulting in effective treatment and molecular remission.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • JAK2 (Janus kinase 2) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CALR (Calreticulin) • CCDC88C (Coiled-Coil Domain Containing 88C)
    |
    LDH elevation
    |
    imatinib
    11d
    Conversational AI-Enabled Precision Oncology Reveals Context-Dependent MAPK Pathway Alterations in Hispanic/Latino and Non-Hispanic White Colorectal Cancer Stratified by Age and FOLFOX Exposure. (PubMed, Cancers (Basel))
    Although MAPK alterations are pervasive in CRC, their distribution varies meaningfully by ancestry, age, and treatment exposure. These findings highlight NF1, MAPK3, RPS6KA4, and PDGFRB as potential biomarkers in EOCRC and H/L patients, supporting the need for ancestry-aware precision oncology approaches.
    Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NF1 (Neurofibromin 1) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • FGF4 (Fibroblast growth factor 4) • CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • MAPK1 (Mitogen-activated protein kinase 1) • DUSP4 (Dual Specificity Phosphatase 4) • MAPK3 (Mitogen-Activated Protein Kinase 3) • RPS6KA6 (Ribosomal Protein S6 Kinase A6)
    |
    5-fluorouracil • leucovorin calcium
    13d
    Chelidonine overcomes P-gp-mediated adriamycin resistance in MCF-7/ADR cells by inhibiting PDGFRβ/PI3K/Akt pathway. (PubMed, Chin Herb Med)
    Chelidonine could effectively overcome the resistance of MCF-7/ADR cells to ADR by targeting the PDGFRβ/PI3K/Akt axis. Meanwhile, these findings highlight the potential of chelidonine as a promising natural chemoresistant agent for BC treatment.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • PDGFRB (Platelet Derived Growth Factor Receptor Beta)
    |
    doxorubicin hydrochloride
    15d
    Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome (clinicaltrials.gov)
    P2, N=80, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | N=60 --> 80
    Enrollment change
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • FIP1L1 (Factor Interacting With PAPOLA And CPSF1)
    |
    imatinib • Jakafi (ruxolitinib)
    25d
    A case report and a literature review of Myeloid/Lymphoid Neoplasm with Eosinophilia and PCM1::JAK2 rearrangement representing as B-cell acute lymphoblastic leukemia B-ALL. (PubMed, Ann Hematol)
    The case highlights the importance of distinguishing de novo lymphoid malignancies from MLN-eo-TK, especially when JAK2 rearrangements are detected. Recognition of the clonal myeloid component during or after lymphoid-directed therapy has important diagnostic and therapeutic implications, supporting the use of targeted JAK2 inhibition in addition to standard chemotherapy.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • JAK2 (Janus kinase 2) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • PCM1 (Pericentriolar Material 1)
    |
    JAK2 rearrangement
    1m
    Comparison of the differentially enriched mutations/pathways between stage II and stage IV dMMR/MSI-H colorectal cancer. (PubMed, Sci Prog)
    Sixty-three mutated genes were unique to stage II tumors, while 36 mutated genes were exclusively present in stage IV tumors. Pathway analyses demonstrated the PI3K-AKT pathway was shared by both stage II and stage IV tumors, whereas multiple other signaling pathways showed disease stage-specific enrichment.ConclusionThere were profound differences in mutational profile and molecular mechanisms between stage II and stage IV dMMR/MSI-H CRC.
    Clinical • Retrospective data • Journal • MSi-H Biomarker • MSI-H • dMMR
    |
    MSI (Microsatellite instability) • FGFR1 (Fibroblast growth factor receptor 1) • STK11 (Serine/threonine kinase 11) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • TSC2 (TSC complex subunit 2) • RAD50 (RAD50 Double Strand Break Repair Protein) • MTHFR (Methylenetetrahydrofolate Reductase) • EPHA3 (EPH receptor A3) • SMAD3 (SMAD Family Member 3)
    |
    MSI-H/dMMR • STK11 mutation